《科学》 第391卷 第6790期 · 2026年3月12日 · 中文解读
KRAS抑制剂在胰腺导管腺癌临床前模型中的癌症拦截作用
Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma
约 49 分钟Research Article Summaries在小程序里点播,20 到 60 分钟做好
这篇讲什么
该研究在KPC小鼠模型中测试了RAS(ON)抑制剂对胰腺癌前病变的拦截效果,发现短期或长期给药可减少癌前病变并显著延长生存期。
原文开头
Recent advances in pharmacology have led to an array of small- molecule inhibitors of the KRAS oncoprotein that have rapidly ad- vanced from preclinical to clinical development due in part to their safety profile (9–11). Major clinical activity, including tumor regressions and prolonged survival, have been reported and have impressively paralleled the antitumor activity observed in multiple mouse models including the KPC model (9, 12). Because almost all PanIN lesions (and PDAC tumors) harbor KRAS mutations, we hypothesized that inhib- iting KRAS early in neoplastic progression might reduce PanIN burden to intercept PDAC. …
摘自《科学》(Science)第391卷 第6790期 · 2026年3月12日。仅引用开头一小段供了解文章,版权归原刊所有,全文请阅读原刊。

微信扫码,在小程序里听完整版
不用登录先听一篇 · 或在微信搜索小程序 晨间信号